Uncoupling protein 3 (UCP3) is a mitochondrial protein that is expressed predominantly in skeletal muscle. It may play a role in altering metabolic function. However, its major physiological roles are not fully understood. Recently de novo expression of UCP3 in rat liver by fenofibrate was reported. We also reported previously that fenofibrate-induced de novo expression of UCP3 contributes to reduction of adipose tissue in obese rats. In the present study, we investigated that fenofibrate-induced expression of UCP3 in rat liver is related with metabolic function such as body weight and hepatic lipid content by time-dependent manner in high-fat diet rats. Eight-week-old male Sprague-Dawley rats were randomly divided into two groups; the high fat diet group (HF, n=16) and fenofibrate-treated high fat diet group (HFF, n=16). The mRNA expression of hepatic UCP3 was detected as early as 1 week of fenofibrate treatment by quantitative real-time PCR and the amount of mRNA was increased time-dependently. The mean body weight of the HFF group was significantly less compared with the HF group after 6 weeks of fenofibrate treatment, even though there was no difference of food intake between the two groups. Rectal temperature was increased during 4 to 6 weeks of fenofibrate treatment and body weight was decreased after 6 weeks of treatment. These results were corresponded with the increased amount of the expression of UCP3 mRNA and protein. We suggest that de novo expression of hepatic UCP3 is increased time-dependently with fenofibrate treatment and that the amount of expression is correlated with metabolic function.
Introduction
Uncoupling proteins (UCPs) were discovered members of the mitochondrial inner membrane carrier family. There were 5 isoforms (UCP1-5) [16, 19, 23] . UCP3 is predominantly expressed in skeletal muscle. Mice overexpressing UCP3 are hyperphagic and lean with increased mitochondrial proton conductance [4] . The function of UCP3 was not completely elucidated. Previous evidences indicate that UCP3 may play functional roles unrelated to the basal uncoupling [9] . In conditions of elevated lipid metabolism, UCP3 might export fatty acid anions, related from an excess of acyl-coenzyme A by mitochondrial thioesterase-1, from the mitochondrial matrix to the cytosol [17] .
Peroxisome proliferation-activated receptor α (PPARα) was the first member of the PPAR family to be described [11] . It is mainly expressed in tissues with high metabolic activity such as the liver, muscle, adipose tissue and others [2, 3] . Fenofibrate is a synthetic ligand for PPARαand it has been used for the treatment of dyslipidemia, especially hypertriglyceridemia [14] . In addition, fenofibrate has been reported to prevent and reduce body weight gain in diet-induced obese rats [7, 15] . This effect on body weight has been suggested that it is related with the enhanced lipid catabolism in the liver mainly through PPARs transcriptional induction of the genes for mitochondrial and peroxisomal oxidative enzymes [5] . UCP genes contain functional PPAR-responsive elements [1, 20] and they may be targets of fenofibrate. In addition, fenofibrate induced de novo expression of UCP3 in rats [12] . Previously our group reported that fenofibrate decreases adiposity and that hepatic uncoupling by fenofebrate contributes to reduction of adiposity [13, 18] In the present study, we investigated whether the times of expression of UCP3 is related with metabolic function in high-fat diet rats. To evaluate the time dependent relation with de novo gene expression of hepatic UCP3, we simultaneously measured the hepatic UCP3 mRNA expression, body weight and body core temperature. Here, we show that the UCP3 expression is time-dependently correlated with body weight and core temperature.
Meterials and Methods

Animal treatment and diet
Male Sprague-Dawley (SD) rats, four-weeks of age (200-225 g, Samtako Bio Korea, Osan, South Korea), were housed at room temperature with 12-h-light/12-h-dark cycle. All of the rats were cared and handled during entire period of experiment by the Guidelines of Animal Experiments by the Korean Academy of Medical Sciences.
They were fed with the standard rat diet and tap water ad libitum for 4 weeks. After then, all of the rats were randomly divided into two groups. The average body weight between the two groups was not significantly different. The first, the high-fat group, was fed with high fat diet ad libitum (n=16, HF). The second, the high-fat with fenofibrate group, was fed with high fat diet, which was mixed with micronized fenofibrate (100 mg/kg, Sigma-ALdrich, St. Louis, MO, USA) (n=16, HFF). The composition of high fat diet was 40% of energy from fat, 20% of energy from protein, and 40% of energy from carbohydrate. Body weight and anal temperature of each rat were monitored weekly. Food intake of each rat was measured daily during the entire experimental period.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) analysis Obtained liver tissue samples were used for RT-PCR. Total RNA was isolated using TRIzol (Invitrogen, Calsbad, CA, USA). Complementary DNA was synthesized from RNA samples by enhanced AMV reverse transcriptase. An aliquot of the reverse transcription reaction was then used for subsequent PCR amplification with specific primers. The sequences of the sense and antisense primers used for amplification were as follows: UCP-3, 5'-GGAGCCATGGCAGTG ACCTGT-3' and 5'-TGTGATGTTGGGCCAAGTCCC-3'; beta-actin, 5'-GTGGTGGTGAAGCTGTAGCC-3' and 5'-GAGA CCTTCAACACCCC-3'. PCR was performed in Gene Amp PCR system 2400 (Perkin-Elmer, Waltham, MA, USA). Amplification of each gene yielded a single band of the expected size (UCP-3, 179 bp; beta-actin 763 bp). Preliminary experiments were carried out with various amounts of cDNA to determine nonsaturating conditions of PCR amplification for all of the genes studied. Therefore, under these conditions, the RT-PCR method used in this study permitted relative quantification of mRNA. The illuminated bands were quantified by Image Gauge (Fujifilm, Japan). The results for the expression of specific mRNAs were presented relative to the expression of the control gene.
Western blot analysis
Liver tissues from rats of HF and HFF groups were subjected to western blot analysis. Isolated proteins were separated on 12% SDS-polyacrylamide gel and transferred electrophoretically onto nitrocellulose membrane using a mini electroblotter (BioRad Laboratories, Hercules, CA, USA). The membrane was blocked with 5% non-fat milk for 1 hr, and then incubated for 2 hr in anti-rat UCP-3 antibody (R&D systems, USA). After washing with TBST, the membrane was incubated for 1 hr with secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoreactive bands were visualized with ECL Plus™ Western Blotting Detection Reagents (GE Healthcare, Pittsburgh, PA, USA). β-actin (42 kDa; Sigma-ALdrich) was used as the internal control.
Measurement of rectal temperature
After 12 hours fasting, all rats inhaled ether and were injected with ketamine (200 mg/kg) into the peritoneum. After the anesthesia administered, the flexible thermometer probe (Temperature controller, DX4-PSSNR, KSC 1614, HANYOUNG, Korea) was placed into the rectal canal. Digital body temperatures were monitored and measured. We evaluated the rectal temperatures two times on different days under the same conditions.
Histological analysis
We sacrificed 2 rats per group weekly. The tissue of liver was collected and weighed. After that, the tissue was rapidly frozen in liquid nitrogen and then was stored at -70 o C until further assay. Hepatic tissues were removed and fixed in 10% neutral buffered formalin, and embedded in paraffin. The sections were stained with hematoxylin and eosin (H & E).
Results
Expression of UCP3 mRNA in liver
We evaluated de novo expression of hepatic UCP3 mRNA by fenofibrate via RT-PCR and western blotting. As shown in Fig. 1A , the expression of UCP3 mRNA in the liver was newly induced by fenofibrate after 2 weeks of fenofibrate treatment. The expression of UCP3 was increased gradually until 6 weeks of fenofibrate treatment. The protein expression of UCP3 was newly induced followed by mRNA expression and gradually increased until 6 weeks of fenofibrate treatment (Fig. 1B) .
Food intake and change of body weight
The mean amount of daily food consumption was 11.4±0.22 g in HF group, 11.8±0.30 g in HFF group. There was no significant difference between the two groups even though daily food intake of fenofibrate treated group seemed to be slightly increased (Fig. 2A) . The changes of mean body weight of the two groups are presented in Fig.  2B . Body weights of both groups were increased as a similar pattern during initial 6 weeks of fenofibrate treatment. After 6 weeks of fenofibrate treatment, the body weight of HFF group was decreased for 2 weeks and maintained for more two weeks. In HF group, the rate of increasing weight was blunted after 6 weeks to 10 weeks. The mean body weight of HFF group was significantly decreased after 6 weeks of fenofibrate treatment.
Body core temperatures
The body core temperature was measured to confirm the relationship between the hepatic UCP3 de novo expression and the increase of body energy expenditure as expressed by increase of body core temperatures. The rectal temperature of HF group was slightly higher at 2 weeks of fenofibrate treatment compared to HFF group. In HFF group, however, the temperature was increased at 4 weeks of fenofibrate treatment and remained at higher state compared to Fig. 3 . Changes of body core temperature. Body core temperature was measured through rectum. Rectal temperature was increased from 4 weeks and maintained to 6 weeks in fenofibrate treated group. This result reflected increased expression of hepatic UCP3 induced by fenofibrate.
HF group (37.7 o C vs. 36.8 o C) (Fig. 3 ).
Histological analysis of the liver
The liver tissues of HF groups showed slight hepatic steatosis on 1 week of high fat diet, gradually progressed on 3 weeks and presented severe hepatic steatosis around portal area on 6 weeks of high fat diet (Fig. 4A, C, E) . In contrast to HF group, the liver tissues of HFF goups showed nearly normal architecture from 1 to 6 weeks of high fat diet with fenofibrate (Fig. 4B, D, F) . As time goes by, the liver of HF group shows moderate to severe fatty changes at 3 and 6 weeks of high fat diet. Fenofibrate treatment, however, induced UCP3, improved hepatic steatosis and nearly normal appearance at 6 weeks even high fat diet feeding.
Discussion
In this study, we found that de novo expression of UCP3 by fenofibrate is timely interrelated with body weight and body core temperature in high fat diet rats. De novo expression of UCP3 in the liver by fenofibrate has been already reported that fenofibrate treatment (320 mg/kg) for 2 months induced de novo expression of UCP3 in high-fat diet fed rats [19] . However, there was little report about time-dependent effect of fenofibrate treatment on UCP3 de novo expression in rat liver. In the present study, we presented that fenofibrate (100 mg/kg) and high-fat diet induced hepatic UCP3 expression as early as 2 week of fenofibrate treatment. We investigated that much less dose of fenofibrate (100 mg/kg) compared to the dose of previous report (320 mg/kg) also could induce de novo expression of hepatic UCP3 mRNA. The amount of the UCP3 expression in liver was increased more and more as time went by. Fenofibrate, and other PPARα agonists, were reported prevented weight gain and even decreased body weight and fat mass in models of genetic or diet-induced obesity in rodents [15, 21, 22] . In our previous report, we also reported that fenofibrate treatment decreased visceral adiposity and improve insulin sensitivity in obese type 2 diabetic rats [13] . The mechanisms of PPARα-induced reduction in weight gain were not fully known yet. One of the suggested mechanisms was that a reduction in fat mass and consequential decrease in leptin production may ultimately induce hypophagia and the resultant decrease in weight gain [21] . In this study there was significantly less weight gain in fenofibrate treated group nonetheless there was no difference in food intake. Dissipating excess energy in liver is a possible therapeutic approach to high-fat diet induced obesity or metabolic disorders. UCP1 was originally identified in brown adipose tissue and demonstrated to mediate non-shivering thermogenesis. UCP1 plays an important role in mediating cold exposure-induced thermogenesis and is also a likely regulator of diet-induced thermogenesis [6, 8] . Enhanced UCP1 expression in the liver increased energy expenditure, decreased body weight, and reduced fat in high-fat diet-induced diabetes and obesity [10] . Alternatively, UCP3 predominantly expressed in muscle, is involved in energy homeostasis [19] . UCP3 may play functional roles not strictly related to the uncoupling. UCP3 can act as a FFA translocator and a role as a regulator of lipids as fuel substrate has been hypothesized in situations where lipid metabolism predominates [9] . De novo expression of UCP3 in liver, provided evidence that UCP3 and mitochondrial thioesterase-1 may concur in regulating fatty acid metabolism and enhancing energy dissipation in liver mitochondria [12] . In this study, we demonstrated that the de novo expression of UCP3 by fenofibrate treatment was related with increase of rectal temperature and less weight gain in high-fat fed rats. This result was similar with dissipating excess energy in the liver by enhanced UCP1 expression in previous report [10] . It might provide more comprehension of the physiological role of UCP3.
Fenofibrate also improves insulin resistance in diet-induced obesity animal models and in subjects with diabetes [7, 13] . Enhanced expression of UCP1 in liver resulted in markedly improved insulin resistance and decreased blood glucose level in diabetes associated with diet-induced obese mice. In this study, de novo expression of hepatic UCP3 by fenofibrate treatment showed no significant effect on peripheral blood glucose level by high-fat diet fed rats. One of the possible causes of the result is that the high-fat fed rats consumed less amount of food than normal chow diet fed control group.
In conclusion, our results indicate that de novo expression of hepatic UCP3 induced by fenofibrate treatment timely increased with metabolic function such as decreasing body weight and increasing body core temperature and prevented hepatic steatosis.
